Your session is about to expire
← Back to Search
Baricitinib for Graft-versus-Host Disease
Study Summary
This trial is exploring the possibility that a JAK1/2 inhibitor called baricitinib may help to decrease the toxicities of allogeneic hematopoietic stem cell transplantation (HSCT) while still allowing the transplant to engraft and providing graft-versus-leukemia (GVL) effects.
- Graft-versus-Host Disease
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 1307 Patients • NCT01710358Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has Baricitinib been trialed elsewhere prior to this undertaking?
"Currently, 32 research studies are taking place surrounding Baricitinib. Of these, 15 have progressed to a Phase 3 level. With the majority of investigations located in Pune, Maharashtra there are also an additional 1417 trial sites across the globe."
Has the FDA sanctioned Baricitinib for use by healthcare providers?
"Baricitinib's safety has been assessed at a score of 1 because it is currently in Phase one trial, where data on efficacy and security are still limited."
What is the sample size of this research endeavor?
"Currently, this clinical trial is not open to new participants. The study was posted on April 7th 2020 and last edited August 30th 2022. If you're searching for other medical trials, there are 171 studies involving disease currently recruiting patients and 32 Baricitinib research programmes seeking volunteers."
Is enrolment in this research endeavor available to participants at the moment?
"Clinicaltrials.gov denotes that this research endeavour, which was initially posted on April 7th 2020 and edited lastly on August 30th 2022, is not currently recruiting patients. However, 203 other studies are presently enrolling participants at the moment."
What ailments have been effectively treated with Baricitinib?
"Hospitalized patients are typically given baricitinib, which is also effective in treating coronavirus disease 2019 (covid‑19), extracorporeal membrane oxygenation treatment, and rheumatoid arthritis."
Share this study with friends
Copy Link
Messenger